PDS Biotechnology Förvaltning
Förvaltning kriterier kontrolleras 4/4
PDS Biotechnology VD är Frank Bedu-Addo, utsedd i Mar 2019, har en mandatperiod på 7.17 år. totala årliga ersättningen är $ 828.31K, bestående av 74.3% lön 25.7% bonusar, inklusive företagsaktier och optioner. äger direkt 1.24% av företagets aktier, värda $ 801.40K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 3.2 år respektive 7.1 år.
Viktig information
Frank Bedu-Addo
Verkställande direktör
US$828.3k
Total ersättning
| VD-lön i procent | 74.29% |
| Anställning som VD | 7.2yrs |
| Ägande av VD | 1.2% |
| Ledningens genomsnittliga anställningstid | 3.2yrs |
| Styrelsens genomsnittliga mandatperiod | 7.1yrs |
Senaste uppdateringar av ledningen
Recent updates
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$33m |
| Dec 31 2025 | US$828k | US$615k | -US$34m |
| Sep 30 2025 | n/a | n/a | -US$35m |
| Jun 30 2025 | n/a | n/a | -US$37m |
| Mar 31 2025 | n/a | n/a | -US$35m |
| Dec 31 2024 | US$2m | US$597k | -US$38m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$5m | US$580k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$2m | US$540k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$7m | US$475k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$815k | US$450k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$3m | US$356k | -US$7m |
Ersättning vs marknad: Frank s total kompensation ($USD 828.31K ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 638.05K ).
Ersättning vs inkomst: Ersättningen från Frank har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Frank Bedu-Addo (59 yo)
Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. Dr. Bedu-Addo was Chief Executive Officer of PDS...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 7.2yrs | US$828.31k | 1.24% $ 801.4k | |
| Chief Operating Officer | 2yrs | US$673.63k | 0% $ 0 | |
| Chief Medical Officer | 2.3yrs | US$677.32k | 0% $ 0 | |
| Principal Financial & Accounting Officer and CFO | 2.4yrs | inga uppgifter | 0% $ 0 | |
| Chief Scientific Officer | 7.2yrs | US$1.68m | 0.22% $ 143.4k | |
| Senior VP | 3.9yrs | inga uppgifter | 0% $ 0 | |
| Controller | no data | inga uppgifter | inga uppgifter |
Erfaren ledning: PDSB s ledningsgrupp anses vara erfaren ( 3.2 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 7.2yrs | US$828.31k | 1.24% $ 801.4k | |
| Independent Director | 7.2yrs | US$89.06k | 0.11% $ 71.0k | |
| Independent Chairman | 7.1yrs | US$119.56k | 0.14% $ 91.5k | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 6.3yrs | US$90.06k | 0.021% $ 13.6k | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Director | 6.1yrs | US$66.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Chair of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter |
Erfaren styrelse: PDSB s styrelse anses vara erfaren ( 7.1 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 02:56 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
PDS Biotechnology Corporation bevakas av 5 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |